68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
- Registration Number
- NCT06387381
- Lead Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Brief Summary
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- At least 18 years of age.
- Signed informed consent.
- Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Exclusion Criteria
- Patients with non-malignant disease.
- Patients with pregnancy.
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- Known or expected hypersensitivity to 68Ga-PSFA or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 68Ga-PSFA 68Ga-PSFA Patients will receive a single administration of 68Ga-PSFA.
- Primary Outcome Measures
Name Time Method Diagnostic efficacy 15 days The sensitivity, specificity, and accuracy of 68Ga-PSFA PET
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The First Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China